The relentless equity issuance to service debt and preferred stock obligations is a hallmark of a company unable to generate cash from operations. The Napo Therapeutics buyout, while consolidating the subsidiary, does not improve the cash position. Traders should expect continued dilution and potential Nasdaq compliance challenges given the sub-$1M public float. Monitor for further debt exchanges or a reverse stock split to maintain listing.
Price Chart
Executive Summary
Jaguar Health issued approximately 3.4 million new common shares across multiple debt-for-equity and preferred-for-equity exchanges, plus a stock-for-stock acquisition of a minority stake in its Napo Therapeutics subsidiary. The transactions eliminate $175k in convertible debt and retire preferred stock, but massively dilute existing holders at a $2M market cap. The Napo Therapeutics buyout consolidates ownership but adds no cash to the balance sheet. Combined with a recently reduced ATM facility, the company continues to manage liabilities via equity issuance rather than operating cash flow, signaling ongoing financial distress for a micro-cap biotech.
Key Facts
- Issued 557,377 shares to Lincoln Alternative Strategies to retire a $175,016.36 convertible note.
- Issued 304,473 shares total to Streeterville Capital across three exchange agreements to retire 9.2 shares of Series Q Preferred Stock.
- Issued 535,000 common shares and a pre-funded warrant for 2,077,255 shares to Joshua Mailman to acquire his entire stake in Napo Therapeutics S.p.A.
- Total new common share issuance from all transactions is approximately 3,474,105 shares, representing massive dilution relative to a ~$2M market cap.
- The Napo Therapeutics acquisition consolidates a majority-owned subsidiary but provides no new operating cash to Jaguar Health.
- All securities were issued in unregistered transactions under Section 3(a)(9) or Section 4(a)(2)/Rule 506.
- The filing follows a recent 424B5 (12 days prior) that reduced the company's ATM capacity to ~$4.78M, indicating ongoing capital needs.
Financial Impact
Massive dilution: ~3.47M new shares issued against a ~$2M market cap. Debt reduced by $175k. No new cash raised.
Risk Factors
- Continued dilution from additional debt-for-equity swaps or warrant exercises.
- Nasdaq delisting risk if the stock price remains below $1.00 given the massive share overhang.
- No path to profitability or positive operating cash flow visible from these transactions.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 10 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-391682 |
| Document: d162139dex105.htm | 0001193125-26-391682 |
| Document: d162139d8k.htm | 0001193125-26-391682 |
| Document: d162139dex103.htm | 0001193125-26-391682 |
| Document: d162139dex104.htm | 0001193125-26-391682 |
| Document: d162139dex102.htm | 0001193125-26-391682 |
| Document: d162139dex101.htm | 0001193125-26-391682 |
| Document: 0001193125-26-391682-index-headers.html | 0001193125-26-391682 |
| Document: 0001193125-26-391682-index.html | 0001193125-26-391682 |
| Document: 0001193125-26-391682.txt | 0001193125-26-391682 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | S-3 | $2.04 | awaiting T+60 | — | $2.37 (−16.18%) |
Oct 8, 2026 18d ago | DEF 14A | $4.79 | awaiting T+60 | — | $2.37 (+50.52%) |
Oct 5, 2026 21d ago | 8-K | $4.73 | awaiting T+60 | — | $2.37 (+49.89%) |
Sep 28, 2026 28d ago | 8-K | $6.02 | awaiting T+60 | — | $2.37 (+60.63%) |
Sep 24, 2026 4w ago | SC 13G/A | $7.70 | awaiting T+60 | — | $2.37 (+69.22%) |
Sep 24, 2026 4w ago | 424B5 | $7.06 | awaiting T+60 | — | $2.37 (+66.43%) |
Sep 24, 2026 4w ago | 8-K | $7.06 | awaiting T+60 | — | $2.37 (+66.43%) |
Sep 21, 2026 5w ago | 8-K | $34.46 | awaiting T+60 | — | $2.37 (−93.12%) |
Sep 15, 2026 5w ago | 8-K | $0.2246 | awaiting T+60 | — | $2.37 (−955.21%) |
Sep 3, 2026 7w ago | 424B5 | $10.41 | awaiting T+60 | — | $2.37 (+77.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers